Analysts’ Perspective: Sarepta Therapeutics (SRPT), Zymeworks (ZYME), EchoStar Corporation (SATS)

Investment Analysts at Barclays upgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares from Equal Weight to Overweight rating while increasing their price target from $55 to $107.

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases.


Brokerage Firm Barclays upgraded Zymeworks Inc. (NYSE:ZYME) shares from Underweight to Equal Weight rating while increasing their price target from $8 to $15.

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada.


EchoStar Corporation (NASDAQ:SATS) shares were upgraded by analysts at Raymond James from Outperform to Strong Buy rating.

EchoStar Corporation provides satellite service operations and video delivery solutions worldwide.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at